id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-346787-uo8k6qic	Jorgensen, Sarah CJ	Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19	2020-05-23		.txt	text/plain	5476	367	51	3 The remdesivir dosing regimen being evaluated in clinical trials (200 mg IV on day 1, then 100 mg IV on days 2 through 5 or 10) was substantiated by in vitro data and bridging the PK with the rhesus monkey experience to humans. Prophylactic and therapeutic remdesivir treatment significantly reduced MERS-CoV-induced clinical signs, viral titers in respiratory specimens and the severity of lung lesions compared to control animals. 14 In the SARS-CoV-2 study, remdesivir was again initiated shortly before viral titers are expected to peak at 12 hours post-inoculation and a dosing regimen equivalent to the regimen being tested in human COVID-19 clinical trials was used (10 mg/kg load ~ 200 mg in humans, then 5 mg/kg daily ~ 100mg daily in humans x 6 days). In a summary of safety data reported by the FDA from the a remdesivir clinical trial comparing 5 and 10day treatment courses in patients with COVID-19, Grade 3 and 4 ALT and/or AST elevations occurred in 7% patients.	./cache/cord-346787-uo8k6qic.txt	./txt/cord-346787-uo8k6qic.txt